News & Resources

Overview

Webcast ImageWebcast
Q1 2015 Orexigen Therapeutics, Inc. Earnings Conference Call (Live)
05/08/15 at 8:30 a.m. ET
Q1 2015 Orexigen Therapeutics, Inc. Earnings Conference Call
Friday, May 8, 2015 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCl and bupropion HCl extended release), which is approved in the United States and is being commercialized there by the companys North American partner, Takeda Pharmaceuticals. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolongedMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$6.61
Change (%) Stock is Down 0.11 (1.64%)
Volume3,231,783
May 05, 2015 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
05/05/15Orexigen Therapeutics to Host First Quarter 2015 Financial Results Conference CallPrinter Friendly Version
04/22/15Orexigen Announces Receipt of Paragraph IV Certification NoticePrinter Friendly Version
04/10/15Orexigen Therapeutics to Speak at the Needham Healthcare ConferencePrinter Friendly Version
03/30/15Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial OfficerPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.